NCT05361954View on ClinicalTrials.gov

Study to Assess the Safety and Preliminary Efficacy of STI-1386 Oncolytic Virus in Relapsed or Refractory Solid Tumors

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

36

Participants

Timeline

Start Date

August 31, 2023

Primary Completion Date

October 31, 2026

Study Completion Date

February 28, 2027

Conditions

CancerCancer of PancreasSarcomaHepatic MetastasisSolid Tumor

Interventions

DRUG

STI-1386

Second generation oncolytic virus

All Listed Sponsors

lead

Sorrento Therapeutics, Inc.

INDUSTRY